Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,680 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Diagnosis Clear all
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 8, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993
View directory record Official record
Conditions
Schizophrenia
Interventions
GXV813, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Bentonville, Arkansas • Pico Rivera, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 8, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 8, 2026, 2:27 AM EDT
Withdrawn Not applicable Interventional

Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine

NCT00934908
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Green Tea, Placebo
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Mobile CBT for Negative Symptoms

NCT03621774
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Mobile-assisted CBT-informed Skills Training, Supportive Contact
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 8, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Motivational Interviewing to Improve Work Outcomes in Schizophrenia

NCT00261716
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
IPS, IE, VOMI
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

NCT00412373
View directory record Official record
Conditions
Schizoaffective Disorder, Psychotic Disorder
Interventions
Placebo, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Targeting Auditory Hallucinations With Alternating Current Stimulation

NCT03221270
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
tACS treatment week, tACS sham week, Maintenance tACS, Maintenance Sham tACS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

NCT02594696
View directory record Official record
Conditions
Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions
Proactive Psychiatry Consultation (PPC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorlilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

NCT00177580
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Pravastatin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

NCT00308360
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, divalproex
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Schizophrenia

NCT00628589
View directory record Official record
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness

NCT02845440
View directory record Official record
Conditions
Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Smoking Cessation
Interventions
Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 2Phase 3 Interventional

Carnosine and Cognitive Training in Schizophrenia

NCT02686697
View directory record Official record
Conditions
Schizophrenia
Interventions
L-Carnosine, Placebo, Cognitive Training
Drug · Behavioral
Lead sponsor
Abraham Reichenberg
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 8, 2026, 2:27 AM EDT
Completed No phase listed Observational

Factors Association With Poor Physical Function in Older Adults With Schizophrenia

NCT01092598
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Individualizing Incentives for Alcohol in the Severely Mentally Ill

NCT03481049
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
Interventions
Usual CM, High-Magnitude CM, Shaping CM
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 8, 2026, 2:27 AM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

NCT00125138
View directory record Official record
Conditions
Parkinson's Disease, Psychotic Disorders
Interventions
Melperone HCl, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Bradenton, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 8, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCT03697252
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 8, 2026, 2:27 AM EDT